# EDGAR Filing Document

**Accession Number:** 0001829658
**File Stem:** 0000859737-26-000093
**Filing Date:** 2026-4
**Character Count:** 11548
**Document Hash:** 314e1e21a24e8567c9003b60d33f26b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000859737-26-000093.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0000859737-26-000093

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260407

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Verstreken Jan
- **CENTRAL INDEX KEY:** 0001829658

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36214
- **FILM NUMBER:** 26852667

**MAIL ADDRESS:**
- **STREET 1:** 250 CAMPUS DRIVE
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HOLOGIC INC
- **CENTRAL INDEX KEY:** 0000859737
- **STANDARD INDUSTRIAL CLASSIFICATION:** X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 042902449
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0928

**BUSINESS ADDRESS:**
- **STREET 1:** 250 CAMPUS DRIVE
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752
- **BUSINESS PHONE:** 5082632900

**MAIL ADDRESS:**
- **STREET 1:** 250 CAMPUS DRIVE
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01752

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Verstreken Jan<br><sub>(Last) (First) (Middle)</sub><br>250 CAMPUS DRIVE<br><sub>(Street)</sub><br>MARLBOROUGH, MA 01752<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Group President, International_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>HOLOGIC INC [ HOLX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-04-07 |  | D |  | 134039 | D | <sup>(1)(2)</sup> | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Non-qualified Stock Option (Right to Buy) | $40.85 | 2026-04-07 |  | D |  |  | 7564 | <sup>(3)</sup> | 2027-02-01 | Common Stock | 7564 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $40.85 | 2026-04-07 |  | D |  |  | 12490 | <sup>(3)</sup> | 2027-12-01 | Common Stock | 12490 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $40.97 | 2026-04-07 |  | D |  |  | 13971 | <sup>(3)</sup> | 2028-11-12 | Common Stock | 13971 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $45.61 | 2026-04-07 |  | D |  |  | 15387 | <sup>(3)</sup> | 2029-11-11 | Common Stock | 15387 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $56.97 | 2026-04-07 |  | D |  |  | 29002 | <sup>(3)</sup> | 2030-07-01 | Common Stock | 29002 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $68.35 | 2026-04-07 |  | D |  |  | 12509 | <sup>(3)</sup> | 2030-11-09 | Common Stock | 12509 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $71.13 | 2026-04-07 |  | D |  |  | 17831 | <sup>(3)</sup> | 2031-11-08 | Common Stock | 17831 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $74.35 | 2026-04-07 |  | D |  |  | 19327 | <sup>(3)</sup> | 2032-11-07 | Common Stock | 19327 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $71.94 | 2026-04-07 |  | D |  |  | 20056 | <sup>(3)</sup> | 2033-11-14 | Common Stock | 20056 | <sup>(3)</sup> | 0 | D |  |
| Non-qualified Stock Option (Right to Buy) | $79.39 | 2026-04-07 |  | D |  |  | 18698 | <sup>(3)</sup> | 2034-11-11 | Common Stock | 18698 | <sup>(3)</sup> | 0 | D |  |
| Performance Stock Units | <sup>(4)</sup> | 2026-04-07 |  | A |  | 31409 |  | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 31409 | <sup>(5)</sup> | 31409 | D |  |
| Performance Stock Units | <sup>(4)</sup> | 2026-04-07 |  | D |  |  | 31409 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 31409 | <sup>(5)</sup> | 0 | D |  |

---

### Footnotes:

(1) Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.  At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").

(2) At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.

(3) For Footnote (3), see Remarks below.

(4) Each Hologic restricted stock unit represents a contingent right to receive one share of Company Common Stock.

(5) Represents the certification of performance results applicable to outstanding Hologic performance stock units ("PSUs") by the compensation committee of the board of directors of Hologic.  Pursuant to the Merger Agreement, for purposes of determining the number of shares of Company Common Stock subject to each PSU, any applicable performance goals were deemed achieved at the greater of (A) the target level of performance and (B) the actual level of performance measured through the latest practicable date prior to the Effective Time.  Pursuant to the Merger Agreement, each outstanding PSU was cancelled and converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock subject to such PSU.

**Remarks:**
(3)  Pursuant to the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (a "Company Option") with an exercise price per share less than the Cash Consideration was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (A) the number of shares of Company Common Stock subject to such Company Option, multiplied by (B) the excess of the Cash Consideration over the exercise price per share of the Company Option, and (ii) one CVR with respect to each share.  Each outstanding Company Option with an exercise price per share equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and $3.00 was cancelled and converted into the right to receive one CVR with respect to each share of Company Common Stock subject to such Company Option, payment in respect of which will be net of the excess of the applicable exercise price per share of the Company Option over $76.00.  Each outstanding Company Option with an exercise price per share of Company Common Stock equal to or greater than the sum of the Cash Consideration and $3.00 was cancelled for no consideration.

**Signature:** /s/ Mark W. Irving, attorney-in-fact for Mr. Verstreken  
**Date:** 2026-04-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**